PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant
NCT01685359
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
80
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
Epoetin Alfa
Sponsor
Azidus Brasil